<PAGE>

--------------------------------------------------------------------------------
--------------------------------------------------------------------------------

                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                             ---------------------

                                   FORM 10-Q

                             ---------------------

(MARK ONE)

   [X]          QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

               FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2001

                                       OR

   [  ]        TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D)
                         OF THE SECURITIES ACT OF 1934

                         COMMISSION FILE NUMBER 0-19946

                             LINCARE HOLDINGS INC.
             (Exact name of registrant as specified in its charter)

<Table>
<S>                                            <C>
                   DELAWARE                                      51-0331330
       (State or other jurisdiction of                        (I.R.S. Employer
        incorporation or organization)                      Identification No.)

              19387 US 19 NORTH                                    33764
                CLEARWATER, FL                                   (Zip Code)
   (Address of principal executive offices)
</Table>

      Registrant's telephone number, including area code:  (727) 530-7700

     Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.  Yes X No  _

     Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.

<Table>
<Caption>
                                                                OUTSTANDING AT
                           CLASS                               NOVEMBER 5, 2001
                           -----                              ------------------
<S>                                                           <C>
Common Stock, $0.01 par value...............................  107,708,618 shares
</Table>

--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
<PAGE>

                             LINCARE HOLDINGS INC.

                                   FORM 10-Q
               FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2001

                                     INDEX

<Table>
<Caption>
                                                                      PAGE
                                                                      ----
<S>     <C>                                                           <C>
PART I.  FINANCIAL INFORMATION
Item 1  Financial Statements (unaudited)
        Condensed consolidated balance sheets.......................    3
        Condensed consolidated statements of operations.............    4
        Condensed consolidated statements of cash flows.............    5
        Notes to condensed consolidated financial statements........    6
Item 2  Management's Discussion and Analysis of Results of
        Operations and Financial Condition..........................    8
Item 3  Quantitative and Qualitative Disclosure Regarding Market
        Risk........................................................    9

PART II.  OTHER INFORMATION
Item 1  Legal Proceedings...........................................   11
Item 2  Changes in Securities.......................................   11
Item 3  Defaults Upon Senior Securities.............................   11
Item 4  Submission of Matters to a Vote of the Security Holders.....   11
Item 5  Other Information...........................................   11
Item 6  Exhibits and Reports on Form 8-K............................   11

SIGNATURE...........................................................   12
</Table>

                                        2
<PAGE>

                         PART I. FINANCIAL INFORMATION

ITEM 1 -- FINANCIAL STATEMENTS (UNAUDITED)

                     LINCARE HOLDINGS INC. AND SUBSIDIARIES

                     CONDENSED CONSOLIDATED BALANCE SHEETS
                                  (UNAUDITED)

<Table>
<Caption>
                                                              SEPTEMBER 30,    DECEMBER 31,
                                                                  2001             2000
                                                              -------------    ------------
                                                                     (IN THOUSANDS)
<S>                                                           <C>              <C>
Current assets:
  Cash and cash equivalents.................................    $    534         $  3,201
  Accounts and notes receivable.............................     130,331          116,838
  Income tax receivable.....................................          --            5,210
  Inventories...............................................       3,086            3,882
  Other.....................................................       2,298            7,121
                                                                --------         --------
          Total current assets..............................     136,249          136,252
                                                                --------         --------
Property and equipment......................................     419,142          364,819
Less: accumulated depreciation..............................     215,225          176,770
                                                                --------         --------
          Net property and equipment........................     203,917          188,049
                                                                --------         --------
Other assets:
  Goodwill..................................................     602,187          540,637
  Intangible assets.........................................       4,939            8,501
  Covenants not to compete..................................         914            1,153
  Other.....................................................       2,299            3,003
                                                                --------         --------
          Total other assets................................     610,339          553,294
                                                                --------         --------
               Total assets.................................    $950,505         $877,595
                                                                ========         ========

Current liabilities:
  Current installments of long-term obligations.............    $ 22,251         $  6,328
  Accounts payable..........................................      20,502           19,812
  Accrued expenses:
     Compensation and benefits..............................      11,722           15,455
     Other..................................................       8,435           10,182
     Income taxes payable...................................       7,072               --
                                                                --------         --------
          Total current liabilities.........................      69,982           51,777
                                                                --------         --------
Long-term obligations, excluding current installments.......     125,837          204,024
Interest rate derivative financial instrument...............       8,266            1,961
Deferred income taxes.......................................      40,775           34,585
Minority interest...........................................         724              798
Stockholders' equity:
  Common stock..............................................       1,210            1,200
  Additional paid-in capital................................     193,654          175,402
  Retained earnings.........................................     686,307          584,693
  Less: treasury stock......................................     176,250          176,845
                                                                --------         --------
          Total stockholders' equity........................     704,921          584,450
                                                                --------         --------
               Total liabilities and stockholders' equity...    $950,505         $877,595
                                                                ========         ========
</Table>

     See accompanying notes to condensed consolidated financial statements.

                                        3
<PAGE>

                     LINCARE HOLDINGS INC. AND SUBSIDIARIES

                CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                  (UNAUDITED)

<Table>
<Caption>
                                               FOR THE THREE MONTHS ENDED       FOR THE NINE MONTHS ENDED
                                              -----------------------------   -----------------------------
                                              SEPTEMBER 30,   SEPTEMBER 30,   SEPTEMBER 30,   SEPTEMBER 30,
                                                  2001            2000            2001            2000
                                              -------------   -------------   -------------   -------------
                                                     (IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
<S>                                           <C>             <C>             <C>             <C>
Net revenues................................   $   206,780     $   186,022     $   596,812     $   513,140
                                               -----------     -----------     -----------     -----------
Costs and expenses:
  Costs of goods and services...............        31,038          31,636          91,147          82,122
  Operating expenses........................        46,525          42,318         135,036         115,810
  Selling, general and administrative
     expenses...............................        42,315          38,230         123,633         108,125
  Bad debt expense..........................         3,101           2,790           8,952           7,697
  Depreciation expense......................        13,815          12,360          40,210          35,635
  Amortization expense......................         5,257           5,302          15,728          14,296
                                               -----------     -----------     -----------     -----------
                                                   142,051         132,636         414,706         363,685
                                               -----------     -----------     -----------     -----------
          Operating income..................        64,729          53,386         182,106         149,455
                                               -----------     -----------     -----------     -----------
Other income (expense):
  Interest income...........................            94             184             313             373
  Interest expense..........................        (3,968)         (5,667)        (11,908)        (12,491)
  Net gain/(loss) on disposal of property
     and equipment..........................           (23)             31             (45)             21
  Unrealized loss on derivative financial
     instrument.............................        (4,670)             --          (6,305)             --
                                               -----------     -----------     -----------     -----------
                                                    (8,567)         (5,452)        (17,945)        (12,097)
                                               -----------     -----------     -----------     -----------
          Income before income taxes........        56,162          47,934         164,161         137,358
Income taxes................................        21,398          18,263          62,547          52,334
                                               -----------     -----------     -----------     -----------
          Net income........................   $    34,764     $    29,671     $   101,614     $    85,024
                                               ===========     ===========     ===========     ===========
  Basic -- earnings per common share........   $      0.32     $      0.28     $      0.95     $      0.80
                                               ===========     ===========     ===========     ===========
  Diluted -- earnings per common share......   $      0.31     $      0.28     $      0.92     $      0.78
                                               ===========     ===========     ===========     ===========
Weighted average number of common shares
  outstanding...............................   107,658,856     105,695,190     107,345,181     106,581,666
                                               ===========     ===========     ===========     ===========
Weighted average number of common shares and
  common share equivalents outstanding......   110,366,857     107,474,008     110,022,308     108,473,088
                                               ===========     ===========     ===========     ===========
</Table>

     See accompanying notes to condensed consolidated financial statements.

                                        4
<PAGE>

                     LINCARE HOLDINGS INC. AND SUBSIDIARIES

                CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                  (UNAUDITED)

<Table>
<Caption>
                                                                 FOR THE NINE MONTHS ENDED
                                                              --------------------------------
                                                              SEPTEMBER 30,      SEPTEMBER 30,
                                                                  2001               2000
                                                              -------------      -------------
                                                                       (IN THOUSANDS)
<S>                                                           <C>                <C>
Cash from operations........................................    $177,140           $145,320
Investing activities:
  Proceeds from sale of property and equipment..............         136                263
  Capital expenditures......................................     (52,793)           (43,935)
  (Increase)/decrease in other assets.......................         498             (1,003)
  Business acquisitions, net of cash acquired...............     (65,120)          (150,238)
                                                                --------           --------
                                                                (117,279)          (194,913)
                                                                --------           --------
Financing activities:
  Proceeds from long-term obligations.......................      52,000            311,000
  Payment of long-term obligations..........................    (125,735)          (206,742)
  Decrease in minority interest.............................        (137)              (128)
  Proceeds from issuance of common stock....................      10,748              1,406
  Proceeds from issuance of treasury stock..................         596                726
  Payment to acquire treasury stock.........................          --            (59,748)
                                                                --------           --------
                                                                 (62,528)            46,514
                                                                --------           --------
Decrease in cash............................................      (2,667)            (3,079)
Cash and cash equivalents, beginning of period..............       3,201              3,699
                                                                --------           --------
Cash and cash equivalents, end of period....................    $    534           $    620
                                                                ========           ========
</Table>

     See accompanying notes to condensed consolidated financial statements.

                                        5
<PAGE>

                             LINCARE HOLDINGS INC.

              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                  (UNAUDITED)

NOTE 1 -- BASIS OF PRESENTATION

     The accompanying condensed consolidated balance sheet as of September 30,
2001, the condensed consolidated statements of operations for the three and nine
month periods ended September 30, 2001 and 2000 and the condensed consolidated
statements of cash flows for the nine months ended September 30, 2001 and 2000
are unaudited and have been prepared in accordance with generally accepted
accounting principles for interim financial information and with the
instructions to Form 10-Q and should be read in conjunction with the
consolidated financial statements and related notes of Lincare Holdings Inc.
(the "Company") on Form 10-K for the fiscal year ended December 31, 2000. In the
opinion of management, all adjustments, consisting of normal recurring accruals,
necessary for a fair presentation of the results of operations for the interim
periods presented have been reflected herein. The results of operations for
interim periods are not necessarily indicative of the results to be expected for
the entire year. The accompanying condensed consolidated balance sheet as of
December 31, 2000 is derived from the Company's audited balance sheet as of that
date.

NOTE 2 -- BUSINESS COMBINATIONS

     During the nine months ended September 30, 2001 the Company acquired, in
unrelated acquisitions, certain assets of 13 companies. Each acquisition was
accounted for as a purchase. The results of the acquired companies are included
in the accompanying consolidated statements of operations since the respective
dates of acquisition.

     The aggregate cost of these acquisitions was as follows:

<Table>
<Caption>
                                                              (IN THOUSANDS)
                                                              --------------
<S>                                                           <C>
Cash........................................................     $65,120
Deferred acquisition obligations............................      11,560
Assumption of liabilities...................................         422
                                                                 -------
                                                                 $77,102
                                                                 =======
</Table>

     The aggregate purchase price was allocated as follows:

<Table>
<S>                                                           <C>
Current assets..............................................     $   678
Property and equipment......................................       3,467
Intangible assets...........................................         115
Goodwill....................................................      72,842
                                                                 -------
                                                                 $77,102
                                                                 =======
</Table>

     The Company is required to immediately adopt the provisions of Statement of
Financial Accounting Standards No. 141 ("SFAS 141"), "Business Combinations",
issued in July 2001. In accordance with SFAS 141, goodwill resulting from
business acquisitions completed after June 30, 2001 has not been amortized. For
the three-month period ended September 30, 2001, $9,537,000 of the Company's
goodwill was affected by the SFAS 141 provisions. Goodwill and certain
intangible assets resulting from business acquisitions before July 1, 2001 will
continue to be amortized through December 31, 2001. On January 1, 2002, the
Company will adopt Statement of Financial Accounting Standards No. 142 ("SFAS
142"), "Goodwill and Other Intangible Assets", which will require that goodwill
and certain intangible assets with indefinite useful lives no longer be
amortized. Adoption of SFAS 142 will require that goodwill and certain
intangible assets be tested for impairment at least annually in accordance with
the provisions of SFAS 142.

     Unaudited pro forma supplemental information on the results of operations
for the nine months ended September 30, 2001 and September 30, 2000 are provided
below and reflect the acquisitions as if they had been combined at the beginning
of each respective period. Effective with the adoption of SFAS 142 on

                                        6
<PAGE>
      NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)

January 1, 2002, the amortization of goodwill and certain intangible assets will
cease. Based on the carrying value of goodwill on the Company's unaudited
balance sheet as of September 30, 2001, the Company anticipates that
amortization expense for fiscal year 2002 will be reduced by approximately
$19,000,000 as a result of adoption of SFAS 142.

<Table>
<Caption>
                                                               FOR THE NINE MONTHS
                                                               ENDED SEPTEMBER 30,
                                                              ----------------------
                                                                2001          2000
                                                              --------      --------
                                                               (IN THOUSANDS EXCEPT
                                                                 PER SHARE DATA)
<S>                                                           <C>           <C>
Net revenues................................................  $613,546      $547,100
                                                              ========      ========
Net income..................................................  $104,940      $ 91,703
                                                              ========      ========
Income per common share:
  Basic.....................................................  $   0.98      $   0.86
                                                              ========      ========
  Diluted...................................................  $   0.95      $   0.85
                                                              ========      ========
</Table>

     The unaudited pro forma financial information is not necessarily indicative
of either the results of operations that would have occurred had the
transactions been effected at the beginning of the respective preceding periods
or of future results of operations of the combined companies.

                                        7
<PAGE>

                             LINCARE HOLDINGS INC.

ITEM 2 -- MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND
FINANCIAL CONDITION

OPERATING RESULTS

     The following table sets forth for the periods indicated a summary of the
Company's net revenues by source:

<Table>
<Caption>
                                            FOR THE THREE MONTHS   FOR THE NINE MONTHS
                                            ENDED SEPTEMBER 30,    ENDED SEPTEMBER 30,
                                            --------------------   --------------------
                                              2001        2000       2001        2000
                                            --------    --------   --------    --------
                                               (IN THOUSANDS)         (IN THOUSANDS)
<S>                                         <C>         <C>        <C>         <C>
Oxygen and other respiratory therapy......  $182,747    $157,069   $523,358    $444,923
Home medical equipment and other..........    24,033      28,953     73,454      68,217
                                            --------    --------   --------    --------
          Total...........................  $206,780    $186,022   $596,812    $513,140
                                            ========    ========   ========    ========
</Table>

     Net revenues for the three months ended September 30, 2001 increased by
$20,758,000 (or 11.2%) compared with the three months ended September 30, 2000.
Net revenues for the nine months ended September 30, 2001 increased $83,672,000
(or 16.3%) compared with the nine months ended September 30, 2000. The increases
in net revenues are attributed to underlying growth in the market for the
Company's products, the Company's sales and marketing efforts that emphasize
quality and customer service, and the effects of business acquisitions completed
by the Company. The Company increased its contribution to net revenues from
oxygen and other respiratory therapy products to 88.4% from 84.4% of net
revenues for the three months ended September 30, 2001, over the comparable
three months ended September 30, 2000. During the three and nine month periods
ended September 30, 2001, the Company reduced its exposure to lower margin
non-respiratory product lines as compared with the prior year periods.

     Costs of goods and services as a percentage of net revenues were 15.0% for
the three months ended September 30, 2001 compared with 17.0% for the three
months ended September 30, 2000. Costs of goods and services as a percentage of
net revenues were 15.3% for the nine months ended September 30, 2001 compared
with 16.0% for the nine months ended September 30, 2000. The decrease in costs
of goods and services as expressed as a percentage of net revenues is attributed
to the Company's continued focus on home respiratory products while successfully
eliminating lower margin non-respiratory product lines from acquired businesses.

     The Company continues to maintain a cost structure that, with increases in
net revenues, has permitted the Company to spread its fixed operating and
overhead expenses over a larger base of revenues, resulting in improvement in
operating income. Operating expenses expressed as a percentage of net revenues
for the three and nine month periods ended September 30, 2001 were 22.5% and
22.6% respectively, as compared to the three and nine month periods ended
September 30, 2000 which were 22.7% and 22.6%, respectively. Selling, general
and administrative expenses as a percentage of net revenues for the three and
nine month periods ended September 30, 2001 were 20.5% and 20.7% respectively,
as compared to the three and nine month periods ended September 30, 2000 which
were 20.6% and 21.1% respectively.

     Amortization expense for the three and nine months ended September 30, 2001
was $5,257,000 and $15,728,000 as compared with $5,302,000 and $14,296,000 for
the three and nine months ended September 30, 2000.

     Operating income for the three and nine months ended September 30, 2001
increased to $64,729,000 and $182,106,000 respectively, compared with
$53,386,000 and $149,455,000 for the three and nine months ended September 30,
2000. The increases in operating income are attributable to the continued growth
in net revenues, a favorable shift in product mix to higher margin products, and
efforts to control costs.

LIQUIDITY AND CAPITAL RESOURCES

     Net cash provided from operating activities was $177,140,000 for the nine
months ended September 30, 2001 compared with $145,320,000 for the nine months
ended September 30, 2000.

                                        8
<PAGE>

     Net cash used in investing and financing activities was $179,807,000 for
the nine months ended September 30, 2001. Activity during the nine-month period
ended September 30, 2001 included the Company's investment of $65,120,000 in
business acquisitions, investment in capital equipment of $52,793,000, proceeds
of $52,000,000 from long-term obligations and payments of $125,735,000 related
to long-term obligations.

     As of September 30, 2001, the Company's principal sources of liquidity
consisted of $66,267,000 of working capital and $226,500,000 available under its
bank credit facility. The Company believes that internally generated funds,
together with funds that may be borrowed under its bank credit facility, will be
sufficient to meet the Company's anticipated capital requirements for the
foreseeable future.

MEDICARE REIMBURSEMENT

     As a supplier of home oxygen and other respiratory therapy services for the
home health care market, the Company participates in Medicare Part B, the
Supplementary Medical Insurance Program, which was established by the Social
Security Act of 1965. Suppliers of home oxygen and other respiratory therapy
services have historically been heavily dependent on Medicare reimbursement due
to the high proportion of elderly suffering from respiratory disease.

     On December 21, 2000 the Medicare, Medicaid and SCHIP Benefits Improvement
and Protection Act of 2000 ("BIPA") was signed into law. Among other things,
BIPA:

     (1) increases payments for durable medical equipment ("DME") items. The DME
        payment increase does not apply to oxygen and oxygen equipment. The
        update is implemented in two steps: for the period January 1, 2001
        through June 30, 2001, DME payments will remain the same as were in
        effect before enactment of BIPA, and for the period of July 1, 2001
        through December 31, 2001, DME items will receive a 3.5% price increase
        plus a "transitional allowance" of 3.3%. As provided under BIPA, the
        transitional allowance will not be taken into account in calculating
        payment amounts after 2001. No DME payment increase is authorized for
        2002.

     (2) requires the U.S. General Accounting Office ("GAO") to study Medicare
        reimbursement for drugs and biologicals and for related services. The
        GAO issued its preliminary report to Congress on September 21, 2001. The
        Department of Health and Human Services ("HHS") is required to revise
        the current payment methodologies based on the GAO's recommendations;
        however, total payments may not exceed the aggregate payments that would
        otherwise have been made under current law.

     On November 29, 1999, the Balanced Budget Refinement Act of 1999 ("BBA
Refinement Act") was signed into law. With respect to the products provided by
the Company, the BBA Refinement Act provides for temporary increases in Medicare
payment rates for durable medical equipment (including oxygen equipment) of 0.3%
in 2001 and 0.6% in 2002.

     Federal and state budgetary and other cost-containment pressures will
continue to impact the home respiratory care industry. The Company cannot
predict whether new federal and state budgetary proposals will be adopted or the
effect, if any, such proposals would have on the Company's business.

ITEM 3 -- QUANTITATIVE AND QUALITATIVE DISCLOSURE REGARDING MARKET RISK

     For the nine months ended September 30, 2001, the Company recorded an
unrealized loss of $6,305,000 ($0.04 per share after taxes) representing a
non-cash valuation adjustment of a derivative financial instrument in accordance
with Statement of Financial Accounting Standards (SFAS) No. 133. The non-cash
valuation adjustment represents the change in market value of the Company's
interest rate collar from December 31, 2000 to September 30, 2001. SFAS No. 133
requires financial statement recognition of the change in market value of
derivative financial instruments. Accordingly, the Company expects to record a
non-cash gain or loss each period to reflect the change in market value of the
interest rate collar until maturity of the instrument. The Company has the
option to terminate the interest rate collar at any time for cash settlement at
fair market value.

                                        9
<PAGE>

     The fair value of the Company's long-term obligations and interest rate
collar are subject to change as a result of changes in market prices or interest
rates. The Company estimates potential changes in the fair value of interest
rate sensitive financial instruments based on a hypothetical decrease (or
increase) in interest rates. The Company's use of this methodology to quantify
the market risk of such instruments should not be construed as an endorsement of
its accuracy or the accuracy of the related assumptions. The quantitative
information about market risk is necessarily limited because it does not take
into account anticipated operating and financial transactions.

     The following table sets forth the Company's estimated impact on the fair
value of its long-term obligations and interest rate collar plus the impact on
earnings resulting from a hypothetical 10% decrease in interest rates.

Estimated fair value of financial instruments (in thousands):

<Table>
<Caption>
                                                                                     (ASSUMING 10%
                                                                              DECREASE IN INTEREST RATES)
                                                                              ---------------------------
                                                                                             HYPOTHETICAL
                                                                                              CHANGE IN
                                                                              HYPOTHETICAL      ANNUAL
                                               FACE     CARRYING     FAIR      CHANGE IN       INTEREST
                                              AMOUNT     AMOUNT     VALUE      FAIR VALUE      EXPENSE
                                             --------   --------   --------   ------------   ------------
<S>                                          <C>        <C>        <C>        <C>            <C>
September 30, 2001:
  Revolving bank credit agreement..........  $  8,000   $  8,000   $  8,000      $   0         $   (32)
  Senior secured notes.....................   125,000    125,000    127,342        443               0
  Interest rate collar.....................         0      8,266      8,266        982             324
December 31, 2000:
  Revolving bank credit agreement..........  $ 78,000   $ 78,000   $ 78,000      $   0         $  (624)
  Senior secured notes.....................   125,000    125,000    125,820        447               0
  Interest rate collar.....................         0      1,961      1,961      1,717             635
</Table>

FORWARD LOOKING STATEMENTS

     Statements contained herein that are not based on historical facts are
forward-looking statements that are based on projections and estimates regarding
the economy in general, the health care industry and other factors which impact
the Company. These statements involve known and unknown risks, uncertainties and
other factors that may cause the Company's actual results, levels of activity,
performance or achievements to be materially different from any results, levels
of activity, performance or achievements expressed or implied by any
forward-looking statements. The estimates relate to reimbursement by government
and third party payors for the Company's products, the costs associated with
government regulation of the health care industry and the effects of competition
and industry consolidation. In some cases, forward-looking statements that
involve risks and uncertainties contain terminology such as "may," "will,"
"should," "could," "expects," "intends," "plans," "anticipates," "believes,"
"estimates," "predicts," "potential" or "continue" or variations of these terms
or other comparable terminology.

     Key factors that have an impact on the Company's ability to attain these
estimates include potential reductions in reimbursement rates by government and
third party payors, changes in reimbursement policies, demand for the Company's
products and services, the availability of appropriate acquisition candidates
and the Company's ability to successfully complete acquisitions, efficient
operations of the Company's existing and future operating facilities, regulation
and/or regulatory action affecting the Company or its business, economic and
competitive conditions and access to borrowed and/or equity capital on favorable
terms.

     In developing its forward-looking statements, the Company has made certain
assumptions relating to reimbursement rates and policies, internal growth and
acquisitions and the outcome of various legal and regulatory proceedings. If the
assumptions used by the Company differ materially from what actually occurs,
then actual results could vary significantly from the performance projected in
the forward-looking statements. The Company is under no duty to update any of
the forward-looking statements after the date of this Form 10-Q.

                                        10
<PAGE>

                         PART II. -- OTHER INFORMATION

ITEM 1 -- LEGAL PROCEEDINGS

     From time to time, the Company receives inquiries from various government
agencies requesting patient records and other documents. It has been Lincare's
policy to cooperate with all such requests for information. The government has
not instituted any proceedings or served Lincare with any complaints as a result
of these inquiries.

     Private litigants may also make claims against the Company for violations
of health care laws in actions known as qui tam suits. In these cases, the
government has the opportunity to intervene in, and take control of, the
litigation. The Company is a defendant in certain qui tam proceedings. The
government has declined to intervene in all unsealed qui tam actions of which
the Company is aware. Lincare intends to vigorously defend these suits should
they proceed.

     As a health care provider, Lincare is subject to extensive government
regulation, including numerous laws directed at preventing fraud and abuse and
laws regulating reimbursement under various government programs. The marketing,
billing, documentation and other practices of health care companies are all
subject to government scrutiny. To ensure compliance with Medicare and other
regulations, regional carriers often conduct audits and request patient records
and other documents to support claims submitted by the Company for payment of
services rendered to patients. Similarly, government agencies periodically open
investigations and obtain information from health care providers pursuant to
legal process.

     Violations of federal and state regulations can result in severe criminal,
civil and administrative penalties and sanctions, including disqualification
from Medicare and other reimbursement programs.

ITEMS 2-5 -- NOT APPLICABLE.

ITEM 6 -- EXHIBITS AND REPORTS ON FORM 8-K

     (a) Exhibits included or incorporated herein: See Exhibit Index.

     (b) The Company did not file a Current Report on Form 8-K during the three
         months ended September 30, 2001.

                                        11
<PAGE>

                                   SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                                  Lincare Holdings Inc.
                                          --------------------------------------
                                                        Registrant

                                                    /s/  PAUL G. GABOS
                                          --------------------------------------
                                                      Paul G. Gabos
                                            Secretary, Chief Financial Officer
                                             and Principal Accounting Officer

November 9, 2001

                                        12
<PAGE>

                               INDEX OF EXHIBITS

<Table>
<Caption>
                                                                               SEQUENTIALLY
 EXHIBIT                                                                         NUMBERED
  NUMBER                                   EXHIBIT                                 PAGE
 -------                                   -------                             ------------
<S>  <C>    <C>  <C>                                                           <C>
A    3.10   --   Amended and Restated Certificate of Incorporation of Lincare
                 Holdings Inc................................................
F    3.11   --   Certificate of Amendment to the Amended and Restated
                 Certificate of Incorporation of Lincare Holdings Inc........
A    3.20   --   Amended and Restated By-Laws of Lincare Holdings Inc........
A    10.20  --   Non-Qualified Stock Option Plan of Registrant...............
A    10.21  --   Lincare Holdings Inc. 1991 Stock Plan.......................
I    10.22  --   Lincare Holdings Inc. 1994 Stock Plan.......................
I    10.23  --   Lincare Holdings Inc. 1996 Stock Plan.......................
I    10.24  --   Lincare Holdings Inc. 1998 Stock Plan.......................
I    10.25  --   Lincare Holdings Inc. 2000 Stock Plan.......................
J    10.26       Lincare Holdings Inc. 2001 Stock Plan.......................
A    10.30  --   Lincare Inc. 401(k) Plan....................................
E    10.31  --   Employment Stock Purchase Plan..............................
E    10.40  --   Employment Agreement dated as of January 1, 1997 between
                 Lincare Holdings Inc. and John P. Byrnes....................
E    10.41  --   Employment Agreement dated as of June 1, 1997 between
                 Lincare Holdings Inc. and Paul G. Gabos.....................
I    10.43  --   Employment Agreement dated as of January 1, 1998 between
                 Lincare Holdings Inc. and Shawn S. Schabel..................
E    10.50  --   Form of Non-employee Director Stock Option Agreement........
E    10.51  --   Form of Non-qualified Stock Option Agreement................
C    10.52  --   Non-Qualified Stock Option Agreements dated as of January
                 23, 1995 between the Registrant and James M. Emanuel........
D    10.53  --   Non-Qualified Stock Option Agreements dated as of January
                 26, 1996 between the Registrant and John P. Byrnes..........
D    10.54  --   Non-Qualified Stock Option Agreements dated as of July 15,
                 1996 between the Registrant and John P. Byrnes..............
G    10.60  --   Three-Year Credit Agreement among Lincare Holdings Inc., as
                 Borrower, Certain Subsidiaries of Borrower from time to time
                 party thereto, as Guarantors, the several Lenders from time
                 to time party thereto and Bank of America, N.A., as Agent...
H    10.61  --   First Amendment to the Three-Year Credit Agreement dated
                 June 20, 2000...............................................
H    10.62  --   Second Amendment to the Three-Year Credit Agreement dated
                 August 21, 2000.............................................
H    10.70  --   Senior Secured Note Purchase Agreement among Lincare
                 Holdings Inc., as Borrower, and several note holders with
                 Bank of America, N.A., as Agent.............................
</Table>

                                        13
<PAGE>

<Table>
<Caption>
                                                                               SEQUENTIALLY
 EXHIBIT                                                                         NUMBERED
  NUMBER                                   EXHIBIT                                 PAGE
 -------                                   -------                             ------------
<S>  <C>    <C>  <C>                                                           <C>
H    10.71  --   Form of Series A Note.......................................
H    10.72  --   Form of Series B Note.......................................
H    10.73  --   Form of Series C Note.......................................
B    22.10  --   List of Subsidiaries of Lincare Holdings Inc................
</Table>

---------------

A   Incorporate by reference to the corresponding exhibit to the Registrant's
    Registration Statement on Form S-1 (No. 33-44672)
B   Incorporate by reference to the Registrant's Form 10-K dated March 22, 1994.
C   Incorporate by reference to the Registrant's Form 10-K dated March 27, 1996.
D   Incorporate by reference to the Registrant's Form 10-K dated March 25, 1997.
E   Incorporate by reference to the Registrant's Form 10-K dated March 26, 1998.
F   Incorporate by reference to the Registrant's Form 10-Q dated August 12,
    1998.
G   Incorporate by reference to the Registrant's Form 10-Q dated November 12,
    1999.
H   Incorporate by reference to the Registrant's Form 10-Q dated November 13,
    2000.
I   Incorporate by reference to the Registrant's Form 10-K dated March 29, 2001.
J   Incorporate by reference to the Registrant's Form 10-Q dated August 1, 2001.

                                        14